Incidence and severity of obesity are increasing worldwide, however, efficient and safe pharmacological treatments are not yet available. Certain MAO inhibitors reduce body weight, although their effects on metabolic parameters have not been investigated. Here, we have assessed effects of a widely used, selective MAO-B inhibitor, selegiline, on metabolic parameters in a rat model of diet-induced obesity.
Introduction
Obesity has become one of the most important public health issues worldwide. In particular, obesity increases the risk of several diseases, such as Type 2 diabetes (Golay and Ybarra, 2005; Wells, 2017) , cardiovascular disease (Eckel, 1997; Poirier et al., 2006) , certain types of cancers (Gallagher and LeRoith, 2015) and depression (Luppino et al., 2010) . Therefore, pharmacological tools which can prevent or treat obesity and the co-morbidities associated with advanced obesity have been intensively studied (Ferdinandy et al., 2014) . However, due to the lack of sufficient efficacy and/or due to safety issues, several drugs have been withdrawn from the market in the last 10 years, for example, rimonabant and sibutramine (Krentz et al., 2016) . Therefore, further research of novel therapeutics is essential for obesity treatment, including repurposing of drugs already in use or development of novel agents.
The MAO isoenzymes are highly expressed in human white adipose tissue, as they are involved in noradrenaline clearance and catecholamine-dependent regulation of lipid metabolism in adipocytes (Pizzinat et al., 1999) . Previous studies have shown that inhibitors of the semicarbazide sensitive amine oxidase (SSAO) administered in combination with certain non-selective and/or irreversible MAO inhibitors can reduce body weight and fat deposition in animal models of diet-induced obesity (Carpene et al., 2007; Carpene et al., 2008) . Mattila et al. showed that administration of pargyline (30 mg·kg À1 ) increased lipolysis and levels of plasma free fatty acid in rats (Mattila and Torsti, 1966) . Furthermore, diet-induced obesity increased MAO activity in the enlarged omental white adipose tissue of dogs (Wanecq et al., 2006) . Therefore, we hypothesized that MAO inhibitors may have favourable metabolic effects in obesity.
Selegiline is a clinically widely used, irreversible and selective inhibitor of MAO-B, which is primarily used to treat Parkinson's disease and depression. However, it has also been shown to have pleiotropic effects not related to the inhibition of MAO-B (Tatton et al., 1994; Tatton et al., 2002) . Békési et al. (Bekesi et al., 2012) showed that selegiline (5-10 mg·day À1 )
significantly decreased liver fat but not body weight in rats fed with a lipid-rich diet (cholesterol 1%, olive oil 10%). However, the effect of selegiline on visceral adiposity, food intake and glucose homeostasis has not been studied so far. Therefore, our aim was to investigate the effect of selegiline treatment on metabolic parameters in a model of induced moderate obesity induced by a high-fat, high-sucrose (HFS) diet, together with alterations in haemodynamic parameters and markers of neuropathy and behavioural patterns.
Methods
All animal care and experimental procedures conformed to Directive 2010/63/EU and was authorized by the regional animal health authority in Hungary (registration numbers: XIV-I-001/450-6/2012). Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Diet-induced experimental obesity: study design
Five to 7-week-old male Long-Evans rats (RRID:RGD_ 2308852) were purchased from Charles River Laboratories (Wilmington, MA, USA). We chose Long-Evans rats for our study as this strain is commonly used for experiments on diet-induced obesity (Li et al., 2008; Estridge et al., 2017) . Furthermore, this strain is leaner than Sprague-Dawley or Wistar rats and, therefore, the effects of mild obesity could be studied with higher reliability in this strain. Furthermore, our laboratory has already experience with this strain in metabolic studies (Koncsos et al., 2016) . Animals were housed in a conventional animal house, in a room maintained on a 12/12-h light/dark cycle and a constant temperature of 21°C. The rats, four to a cage, were housed in a polyethylene EUROSTANDARD TYPE IV S cages (480 × 375 × 210 mm) containing corncob bedding from J. Rettenmaier & Söhne GmbH & Co. Animals were allowed access to food and water ad libitum. After one week for acclimatization, rats were randomly divided into two groups: control (CON; n = 20) and highfat, high-sucrose group (HFS; n = 20). The CON group was fed a control rat chow, whereas the HFS group was fed a chow supplemented with 20% lard and 15% sucrose as an HFS diet (Table 1) .
From week 16, groups of animals were further randomly divided and injected s.c. with 0.25 mg·kg À1 selegiline (CON + S and HFS + S) or vehicle (CON, HFS) once daily (n = 10 in each group). Our and other work groups' earlier experiments had showed that rats treated with daily subcutaneous dose of 0.25 mg·kg À1 selegiline selectively inhibited the B form of the enzyme, leaving the activity of the A form practically unchanged. With a higher (1 mg·kg À1 ) dose, the selectivity was nearly lost (Knoll, 1978; Heinonen et al., 1994) . Body weights were measured monthly. Blood was taken from the saphenous vein and fasting blood glucose levels measured every month (Accu-Check; Roche, Basel, Switzerland). At week 24, the oral glucose tolerance test (OGTT) was performed on conscious overnight fasted rats with oral administration of 1.5 g·kg À1 glucose and measurements of plasma glucose levels at 15, 30, 60 and 120 min. The insulin tolerance test (ITT) was also performed at week 24 in overnight fasted rats. Insulin (0.5 IU·kg À1 , Humulin R; Ely Lilly, Utrecht, the Netherlands) was injected i.p., and plasma glucose levels were checked at 15, 30, 45, 60, 90 and 120 min. At week 24, after 1 day acclimatization, food intake was observed for 24 h in a metabolic cage. At week 25 of the diet, animals were anesthetized by pentobarbital (60 mg·kg À1 , i.p.; Euthasol; Produlab Pharma, Raamsdonksveer, the Netherlands). After haemodynamic measurements, animals were sacrificed and epididymal and interscapular brown fat tissue, markers of adiposity, were isolated, and their weights were measured. Blood and tissue samples were collected and stored at À80°C (Figure 1. ). To exclude the natural variability between weights, organ weights were normalized to tibia length (Tsujita et al., 2006; Nemeth et al., 2016) .
Evaluation of whole body fat
To assess obesity, CT measurements were performed on NanoSPECT/CT PLUS (Mediso, Budapest, Hungary) at week 24. The semicircular CT scanning was acquired with a 55 kV tube voltage, 500 ms exposure time, 1:4 binning and 360 projections in 18 min. During the acquisitions, rats were placed in a prone position in a dedicated rat bed and were anaesthetized with 2% isoflurane in oxygen. Temperature of the animals was kept at 37.2 ± 0.3°C during imaging. In the reconstruction, 0.24 mm in-plane resolution and slice thickness were set, and Butterworth filter was applied (volume size: 76.8 × 76.8 × 190 mm) . Images were further analysed with VivoQuant (inviCRO, Boston, MA, USA) dedicated image analysis software products by placing appropriate volumes of interest on the whole body fat of animals. The aim of segmentation was to separate the fat from other tissues. The connected threshold method helped to choose the adequate attenuated pixels for fat tissue analysis, and then the isolated points were detected by erode four voxel and dilate four voxel steps. After the measurements, animals recovered from anaesthesia. Adiposity index was calculated by the following formula: (CT whole body adipose tissue volume/body weight) × 100. Subcutaneous and total visceral fat volume were evaluated on CT images by CTan software (Bruker microCT, Kontich, Belgium).
Immunohistochemistry
For immunohistochemistry, deparaffinized sections were treated for antigen retrieval (pH = 6 citrate buffer, at 95°C Data are expressed as g/100 g or otherwise noted.
Figure 1
Experimental protocol. Male Long-Evans rats were fed with CON (n = 10) diet or with HFS (n = 10) diet for 25 weeks; CON + S (n = 10) and HFS + S (n = 10) groups were treated with 0.25 mg·kg À1 selegiline (S) from week 16 to 24. Body weights and blood glucose were measured monthly. Neuropathy and behavioural tests were measured at weeks 22-23. OGTT, ITT, metabolic cage and CT were performed at week 24. Haemodynamic analysis was performed at week 25. Tissue sampling was performed after terminal procedures.
for 15 min). After blocking endogenous peroxidase activity (Bloxall, Vector Laboratories, Burlingame, CA, USA), the sections were blocked in appropriate sera (2.5% goat serum in PBS). The primary antibody recognizing the monocyte/macrophage-specific protein Iba-1 (Wako Pure Chemical Industries, Chuo-Ku, Osaka, Japan) was incubated with the sections overnight in blocking solution at 4°C. After the primary antibody incubation, the sections were washed three times in PBS and incubated for an hour with an anti-rabbit IgG peroxidase polymer (ImmPress reagents, Vector Laboratories, Burlingame, CA, USA). Secondary antibodies were washed three times for 10 min, and the specific signal was developed with diaminobenzidine [ImmPACT DAB EqV Peroxidase (HRP) Substrate, Vector Laboratories, Burlingame, CA, USA]. The specific staining was visualized, and images were acquired using a Leica DM3000 LED microscope and MC 190 HD camera (Leica Microsystems, Wetzlar, Germany). After routine formalin-fixed paraffin-embedded specimen processing, 4 μm thick tissue sections were prepared and stained with haematoxylin and eosin, for histological evaluation of adipocyte morphology. Adipocyte cross-sectional area was measured with the ImageJ based software, Adiposoft (Galarraga et al., 2012) .
Adipocyte cross-sectional area
Adipocyte cross-sectional area was measured with the ImageJbased software, Adiposoft (Galarraga et al., 2012) . Images of adipocyte cross-sectional area were subtracted using ImageJ and then analysed with Adiposoft without using automated method. Cells which were smaller than 25 μm in diameter were excluded. Analysed images were edited using manual method in Adiposoft.
Cells on the borders of image were excluded, separated sections that clearly belonged to one cell were merged together, and cells which were not recognized by software were added and analysed manually. Adipocyte tissue areas in μm 2 were then further used for analysis.
Total RNA isolation
Total RNA from white adipose tissue (epididymal) was extracted with a precipitation method. Briefly, RNAzol ® RT (Sigma, USA) was added to each sample and homogenized with TissueLyser (Qiagen, Germany). Homogenates were centrifuged, and DNA and protein were precipitated with nuclease-free water. Furthermore, 4-bromoanisole (Sigma), phase separation step was incorporated to maximize the DNA elimination. Total RNA was precipitated with isopropanol (vWR, USA), and pellet was washed twice with ethanol (vWR, USA). Finally, total RNA was resuspended in nucleasefree water. RNA concentrations were measured with NanoDrop (Thermo Scientific, Waltham, USA).
cDNA synthesis and qRT-PCR 
Measurement of liver lipid content

Haemodynamic measurements
Arterial BP measurements were performed using a 2F microtip pressure microcatheter (SPR-838, Millar Instruments, Houston, USA). Rats were anaesthetized with pentobarbital (60 mg·kg À1 , i.p., Produlab Pharma), tracheotomized, intubated and artificially ventilated, while core temperature was maintained at 37°C. Thereafter, the catheter was inserted into the right carotid artery and advanced into the ascending aorta. After stabilization for 5 min, arterial BP curve was recorded by the PowerLab data acquisition system (AD Instruments, Colorado Springs, USA), stored, displayed and analysed on a personal computer by the LabChart Software System (AD Instruments) to calculate heart rate, systolic and diastolic BP values.
Behaviour and nociceptive tests
To test if altered caloric intake and obesity may influence motor activity, motility was measured with a three channel CONDUCTA system (EXPERIMETRIA Ltd. Hungary). Animals were placed to one of the 48 × 48 × 40 cm observation boxes for 30 min. Their movements were detected with IR sensors. The time spent with four mutually exclusive movement types were analysed: rearing (vertical activity), immobility (complete motionlessness), ambulation (horizontal activity) and local movements (non-locomotor activity).
Novel object recognition assay was performed to assess the effects of selegiline on HFS diet-induced cognitive dysfunctions. This assay is a model for the investigation of visual recognition memory in rodents. The task procedure consists of three phases: Day 1 -habituation to the test box for 3 min; Day 2 -familiarization with two identical objects, (trial 1, t1); and Day 3 -test phase: after 24 h intertrial delay, one of the familiar objects was replaced by a novel object and the exploration time of each object was measured for 3 min (trial 2, t2). The animals were observed through a video camera system. Recognition memory was characterized by the discrimination index (DI): (t2 novel À t2 fam )/(t2 novel + t2 fam ) × 100, where t2 novel and t2 _fam are exploration time of novel and familiar object, respectively, in the test phase in seconds. Therefore, higher DI indicates better recognition memory.
To investigate sensory changes in prediabetes and obesity related to potential neuropathic complications, we performed two mechano-nociceptive tests. The dynamic plantar aesthesiometer (DPA; Ugo Basile Model No. 37450, Comerio, Italy) is a modified method of the classic von Frey assay to assess touch sensitivity. The animals were put in mesh bottom plastic boxes. A blunt-ended thin metal filament was targeted to the middle region of the plantar surface of the hind paws with an increasing force up to the maximum of 50 g with 10 g·s À1 ramp. Each paw was tested three times, and the touch sensitivity thresholds were determined. As this touch stimulus is basically non-painful for the rat under normal conditions, decreased sensitivity threshold is considered as mechanical allodynia. The Randall-Selitto test (Ugo Basile Model No. 18476, Comerio, Italy) measures the pressure sensitivity of the paws. The cone-shaped probe of the instrument applied a continuously increasing pressure on the hind paw of the loosely held, restrained rat and the pressure threshold of the withdrawal reaction was registered. Each hind paw was tested in this assay once. Unlike the touch stimulus, this pressure represents a mild painful stimulus under healthy conditions and ,therefore, a decreased pressure withdrawal threshold shows mechanical hyperalgesia. The Randall-Selitto test was performed after the DPA measurement to avoid the possible influence of the compression on touch sensitivity.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) . Data analysis was performed in a blinded fashion. Group sizes were chosen based on previous experience (Koncsos et al., 2016) . Data are expressed as mean ± SEM. Statistical analysis was performed by two-way ANOVA using Fisher's LSD as post hoc test only if F achieved P < 0.05, and there was no significant variance inhomogeneity by Prism 6 (GraphPad, GraphPad Software, USA). For motor activity, multivariate ANOVA was performed as statistical evaluation. Differences were deemed significant when P < 0.05.
Materials
Selegiline was purchased from Cayman Chemical (Ann Arbor, MI, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY (Harding et al., 2018) and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
HFS diet elevated body weight despite a similar caloric intake
To investigate the effect of chronic HFS diet and selegiline treatment in rats, we measured body weight, food and caloric intake. The body weight was slightly but significantly elevated in HFS and HFS + S groups from week 16 with a 14% increase at the end of the study, showing moderate obesity (Figure 2A, B) . Observations in metabolic cages showed that food intake was lower in HFS and HFS + S groups resulting in similar caloric intake in all groups ( Figure 2C , D). Chronic selegiline had no influence on body weight or food intake. In the HFS group, one animal died due to procedural error.
Selegiline reduced HFS diet-induced adiposity
To determine the effects of HFS diet and selegiline treatment on obesity, we evaluated adiposity and measured weights of epididymal and brown adipose tissues and organ weights. Selegiline treatment significantly decreased HFS diet-induced adiposity ( Figure 3A, D) . Here, we found that total visceral and subcutaneous fat volumes increased significantly on the HFS diet and that selegiline treatment reduced these elevations in total visceral and subcutaneous fat depots ( Figure 3B , C). For histological evaluation of adipocyte morphology, epididymal adipose tissue sections were prepared and stained with haematoxylin and eosin ( Figure 3E ). Furthermore, we measured the size of adipocytes in epididymal and inguinal white adipose tissues, but neither diet nor selegiline had any influence on adipocyte area (Supporting Information  Table S2 ). The weight of epididymal adipose tissue but not that of perirenal or brown adipose tissue was elevated by HFS diet, compared with the control diet group. Furthermore, selegiline treatment significantly decreased epididymal adipose tissue weight in HFS diet, after normalization to tibia length (Table 2) . We found no significant differences in organ weights, plasma leptin and lipid levels. We assessed the blood level of thyroid hormone T3 and T4, and we found no difference in their levels due to diet or selegiline treatment (Table 3) . To assess the effects of selegiline on lipid metabolism, we measured free fatty acid levels in the blood, but we found no differences due to diet or selegiline treatment (Table 3) . To investigate whether selegiline affected liver lipid Data are mean ± SEM. CON, control (n = 10); CON + S, control + selegiline (n = 10); HFS, high-fat, high-sucrose (n = 9); HFS + S, high-fat, high-sucrose + selegiline (n = 10). content in animals on HFS diet, we measured hepatic total cholesterol and triglyceride levels and found them to be significantly higher in HFS groups, compared with CON groups. However, selegiline had no effect on hepatic lipid levels in our model of obesity (Table 3) .
Selegiline had no effect on glucose homeostasis impaired by HFS diet
In our study, we aimed to characterize the changes in glucose homeostasis induced by the chronic HFS diet. OGTT and ITT tests showed that insulin tolerance developed in rats on the HFS diet by week 24 ( Figure 4A , B), although fasting blood glucose level ( Figure 4C ) or plasma and pancreas insulin levels (Table 3) were not affected by diet or selegiline treatment. These results suggest that chronic HFS diet led to the development of a prediabetic state.
Selegiline interferes with glucose uptake and lipid metabolism via modulating expression of Glut1, Srebp-1c and Ndufa1 in HFS diet
To examine glucose uptake in visceral white adipose tissue, we measured expression of Glut1 and Glut4 expression and found that the HFS diet significantly increased gene expression of Glut1 but not of Glut4. Furthermore, the HFS diet induced the expression of Dgat and Gapdh in adipose tissue, but selegiline treatment had no effect on these parameters. We also found that neither diet nor selegiline had any influence on gene expression of Acc, Pnpla2 and Cd36 in white adipose tissue. However, we found that HFS diet induced Srebp-1c expression and selegiline treatment tended to reduce Srebp-1c gene expression in white adipose tissue in HFS diet. Data are mean ± SEM. CON, control (n = 8); CON + S, control + selegiline (n = 8); HFS, high-fat, high-sucrose (n = 8); HFS + S, high-fat, high-sucrose-+ selegiline (n = 8). a P < 0.05, significantly different from CON. b P < 0.05, significantly different from HFS. Data are mean ± SEM. CON, control (n = 8); CON + S, control + selegiline (n = 10); HFS, high-fat, high-sucrose (n = 8); HFS + S, high-fat, highsucrose + selegiline (n = 7); T3, triiodothyronine; T4, thyroxine. a P < 0.05, significantly different from control diet groups.
Figure 4
HFS diet impaired glucose homeostasis. (A) OGTT results at week 24; (B) fasting blood glucose levels during OGTT; (C) ITT at week 24; (D) fasting blood glucose levels during ITT; (E) fasting blood glucose levels during feeding period. Data are presented as mean ± SEM. *P < 0.05, significantly different from CON, ‡ P < 0.05, significantly different from CON + S, † P < 0.05, significantly different from control diet groups. CON, control (n = 10); CON + S, control + selegiline (n = 10); HFS, high-fat, high-sucrose (n = 9); HFS + S, high-fat, high-sucrose + selegiline (n = 10).
Figure 5
Gene expression of lipid and carbohydrate metabolism markers. Data are presented as mean ± SEM. *P < 0.05, significantly different from CON, † P < 0.05, significantly different from control diet groups. CON, control (n = 10); CON + S, control + selegiline (n = 10); HFS, high-fat, high-sucrose (n = 9); HFS + S, high-fat, high-sucrose + selegiline (n = 10).
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Selegiline reduces HFS diet-induced inflammation in white adipose tissue by modulating expression of Ccl3
To investigate whether selegiline has effect on inflammation in the white adipose tissue, we measured gene expression of chemokines as markers of adipose tissue inflammation. We found no difference in expression of Ccl2 and in the number of macrophages in the epididymal and inguinal white adipose tissue (Supporting Information Table S3 ); however, HFS diet induced gene expression of Ccl3 which was reduced by selegiline treatment (Figure 6 ).
Selegiline decreased arterial systolic pressure in control diet
To examine whether HFS diet or selegiline influences haemodynamic parameters, we measured heart rate, arterial systolic and diastolic pressures. We found that selegiline significantly decreased systolic pressure in rats fed control diet but that this effect was abolished in rats on the HFS diet (Table 4) .
HFS diet and selegiline did not induce behavioural alterations or sensory neuropathy
As selegiline improves cognitive functions in aged animals (Brandeis et al., 1991) and because high-fat diets have been shown to induce cognitive decline (Noble et al., 2014) , we assessed the effect of selegiline on cognition in our model. To investigate the movement pattern and recognition memory, we performed a spontaneous motor activity test and novel object recognition test at the end of our study. Neither HFS diet nor selegiline treatment significantly affected the motor activity (Table 5) . Furthermore, all groups showed a moderate level of recognition memory: rats explored the novel object for 60-80% longer than the familiar one. Neither selegiline treatment nor HFS diet caused statistically significant alterations in the performance of the animals (Table 6 ).
To detect neuropathy and neuropathic pain induced by the HFS diet, we performed two nociceptive tests. For testing pressure hyperalgesia, we performed Randall-Selitto paw pressure test, and for testing mechanical allodynia, we used DPA. Results showed no difference in pain thresholds between groups either for DPA or the Randall-Selitto assay (Table 7) . These results indicate that disturbed glucose homeostasis did not cause neuropathy.
Discussion
This is the first demonstration that selegiline, an irreversible MAO-B inhibitor, significantly decreased adiposity but not body weight in HFS diet by reducing fat deposition. We also Figure 6 Selegiline reduces HFS diet-induced adipose tissue inflammation. (A) Gene expression of inflammatory markers. (B) Immunohistochemistry of Iba1 in epididymal adipose tissue. Data are presented as mean ± SEM. *P < 0.05, significantly different from CON, # P < 0.05, significantly different from HFS. → 'crown-like' structures. CON, control (n = 10); CON + S, control + selegiline (n = 10); HFS, high-fat, high-sucrose (n = 9); HFS + S, high-fat, high-sucrose + selegiline (n = 10).
Selegiline reduces adiposity in high-fat diet found that selegiline may have affected energy metabolism in the adipose tissue and that selegiline reduced adipose tissue inflammation. However, HFS diet-induced insulin resistance was not affected by selegiline treatment. In our experiment, Long-Evans rats fed with HFS diet for 25 weeks had significantly but moderately higher body weight and visceral fat deposition, compared with controls. Although with an extended period of feeding animals could have developed morbid obesity, our aim was to investigate the effect of selegiline in a model of mild obesity, as mild obesity is considerably more common than morbid obesity (Hruby and Hu, 2015) . Here, we found that selegiline treatment did not cause significant weight gain in rats either on control or HFS diets and that selegiline treatment significantly decreased HFS diet-induced subcutaneous and visceral adiposity. These findings highlight the advantage of selegiline as an antidepressant medication, as first-line antidepressants are known to induce weight gain as a side effect (Uguz et al., 2015; Abosi et al., 2018) , whereas our results show that selegiline is devoid of such effect, indeed, it may reduce body fat content.
Visceral adiposity is a major risk factor for cardiovascular disease and for diabetes (Gonzalez et al., 2017) . The effect of MAO inhibition has been previously investigated in models of metabolic disorders. For example, Carpéné et al. demonstrated that combined administration of semicarbazide (300 μmol·kg À1 ·day À1 ), an inhibitor of SSAO, and of Table 4 Haemodynamic parameters
CON CON + S HFS HFS + S
Heart rate (bpm) 408 ± 8 387 ± 13 412 ± 14 393 ± 13
Arterial systolic pressure (mmHg) 174 ± 2 146 ± 11 a 175 ± 8 159 ± 8
Arterial diastolic pressure (mmHg) 138 ± 2 119 ± 8 135 ± 6 130 ± 7
Data are mean ± SEM. CON, control (n = 6); CON + S, control + selegiline (n = 5); HFS, high-fat, high-sucrose (n = 5); HFS + S, high-fat, high-sucrose-+ selegiline (n = 5). a P < 0.05, significantly different from CON.
Table 5
Measurement of spontaneous locomotor activity Time (min) CON CON + S HFS HFS + S Ambulation 3.6 ± 0.3 3.9 ± 0.3 3.2 ± 0.2 3.4 ± 0.3
Local movement 9.3 ± 0.2 8.7 ± 0.3 9.2 ± 0.2 9.4 ± 0.3 Immobility 14.6 ± 0.6 13.8 ± 0.6 14.5 ± 0.4 14.7 ± 0.4
Rearing 2.5 ± 0.3 3.5 ± 0.3 3.1 ± 0.3 2.5 ± 0.2
Data are mean ± SEM. CON, control (n = 10); CON + S, control + -selegiline (n = 10); HFS, high-fat, high-sucrose (n = 9); HFS + S, highfat, high-sucrose + selegiline (n = 10). Table 6 Novel object recognition assay CON CON + S HFS HFS + S t2 novel (s) 16.9 ± 3.5 13.5 ± 2.3 11.0 ± 1.5 12.0 ± 1.2 t2 familiar (s) 10.0 ± 2.1 7.8 ± 0.9 6.1 ± 0.8 6.5 ± 0.7
Data are mean ± SEM. t2 novel , exploration time of novel object; t2 familiar , exploration time of familiar object; CON, control (n = 7); CON + S, control +-selegiline (n = 9); HFS, high-fat, high-sucrose (n = 8); HFS + S, high-fat, high-sucrose + selegiline (n = 8). Table 7 Assessment of neuropathy
CON CON + S HFS HFS + S
Pressure sensitivity threshold (g) 195 ± 4.7 207.5 ± 4.7 201.9 ± 12.2 207.8 ± 10.3
Touch sensitivity threshold (g) 47.4 ± 1.9 47.8 ± 1.4 47.9 ± 2.1 50 ± 0.0
Data are mean ± SEM. CON, control (n = 10); CON + S, control + selegiline (n = 10); HFS, high-fat, high-sucrose (n = 9); HFS + S, high-fat, highsucrose + selegiline (n = 10).
another MAO-B inhibitor, pargyline (10 mg·kg À1 ·day À1 ), to young male obese Zucker rats (Carpene et al., 2007) or non-obese Wistar rats (Carpene et al., 2008) significantly reduced body weight gain and fat deposition by reducing energy intake. Furthermore, pargyline alone was shown to reduce body weight, to a minor extent, in obese Zucker rats (Carpene et al., 2007) and in control rats (Mattila and Torsti, 1966) at doses of 10 and 30 mg·kg À1 ·day À1 respectively. These findings are partly in contrast with our current findings, since although we found that selegiline at human-equivalent therapeutic doses reduced adiposity induced by the HFS diet, it neither reduced body weight in control rats nor affected caloric-or food intake. These discrepancies might be attributed to the different models of metabolic disorders, to the different doses of MAO inhibitors used or to the combined inhibition of amine oxidases in the previous study. Therefore, MAO-B inhibition by therapeutic doses of selegiline in the present study has beneficial effect only in obesity by reducing adiposity. However, if MAO inhibitors are applied at higher doses, they might also affect body fat distribution in non-obese conditions as well (Mattila and Torsti, 1966) . The exact mechanism behind the adiposity-decreasing effect of MAO-B inhibitors is unclear. Here, we found that HFS diet significantly increased gene expression of Glut1 but not of Glut4. Furthermore, selegiline treatment slightly but not significantly reduced gene expression of Glut1 in rats on the HFS diet. Supra-micromolar concentrations of selegiline prevented the stimulation of glucose uptake induced by 5-HT in cardiomyocytes, indicating a role of MAO in this process (Fischer et al., 1995) . These data indicate that selegiline might modulate insulin-independent glucose uptake in adipose tissue. Furthermore, the HFS diet induced expression of Dgat and Gapdh in adipose tissue, but selegiline treatment had no effect on these parameters. We also found that neither diet nor selegiline had any influence on gene expression of Acc, Pnpla2 and Cd36 in white adipose tissue. However, HFS diet induced Srebp-1c expression and selegiline treatment tended to reduce Srebp-1c gene expression in white adipose tissue in HFS diet, suggesting that selegiline might modulate certain aspects of lipid metabolism in the adipose tissue. Effects of MAO-B inhibition on metabolism have been previously studied. For example, pargyline reduced lipoprotein lipase activity in adipose tissue (Mattila and Torsti, 1966) . Elsewhere, phenelzine, an antidepressant with a potent MAO-and SSAO-inhibitory activity, prevented cell triglyceride accumulation and adipose conversion and also reduced expression of several key adipogenic transcription factors, such Srebp-1c (Chiche et al., 2009) , which is in line with our current findings. We also assessed parameters of metabolism from the circulation. In our study, selegiline treatment did not affect plasma leptin, free fatty acid level or lipid levels both in control and in HFS animals. These results are compatible with the data reported by Carpéné et al. where treatment with pargyline did not alter lipid metabolism in obese rats (Carpene et al., 2007; Carpene et al., 2008) . However, elsewhere, an increase in lipolytic rate of adipose tissue and elevation of plasma free-fatty acids were reported in non-obese rats treated with pargyline or non-selective MAO inhibitors iproniazid or pheniprazine (Mattila and Torsti, 1966) . We also investigated the effect of selegiline on hormonal regulation of metabolism. Here, we found that selegiline had no effect on the level of T3 or T4 either in control or obese rats which is in line with a previous publication where MAO-B inhibition did not modify thyroid hormones in lean rats (Cabanillas, et al., 1994) .
Browning of white adipose tissue indicates a metabolic activation. We hypothesized that selegiline might influence this phenomenon but our results showed that selegiline treatment seems not to affect the browning process per se. Adipose tissue inflammation is a severe consequence of obesity. MAO-A was recently proposed to play a role regulating alternative macrophage activation via the IL-4 / IL-13 signalling pathway (Cathcart and Bhattacharjee, 2014) . Moreover, several studies have shown that macrophages are capable of catecholamine synthesis, which play essential role in lipolysis in the adipose tissue (Nedergaard et al., 2011) . Nguyen et al. found that macrophages secrete catecholamines to induce lipolytic/thermogenic gene expression changes in brown and white adipose tissues (Nguyen et al., 2011) . In contrast with these findings, a recently published study showed that adipose tissue macrophages do not participate in catecholamine synthesis (Fischer et al., 2017) . Nevertheless, there is recent evidence that noradrenaline was transported into neuron-associated macrophages and degraded by the activity of MAO-A (Pirzgalska et al., 2017) , thus proposing MAO inhibition as a tool to promote lipolysis. Although we have growing evidence that MAO-A activity may have important role in inflammatory macrophages, there is no information on the role of MAO-B in macrophages as well as in adipocytes. Here, we found no difference in expression of the chemokine CCL2 and in the number of macrophages in the epididymal and inguinal white adipose tissue; however, HFS diet induced gene expression of another chemokine CCL3 which was reduced by selegiline treatment. Therefore, inflammation of white adipose tissue might be limited by selegiline. However, measurement of other parameters, for example, other cytokines might be necessary to further elaborate on this aspect.
These results indicate that selegiline may influence glucose and lipid metabolism of white adipose tissue and that selegiline may also alleviate inflammation in white adipose tissue. However, to reveal the exact mechanisms of these pleiotropic effects of selegiline, further experiments are needed.
In our current study, insulin resistance developed in rats on the HFS diet, but neither plasma nor pancreas insulin levels nor insulin resistance were affected by selegiline treatment. These results suggest that the prediabetic state induced by the chronic HFS diet was not alleviated by MAO-B inhibition. In contrast to our results, earlier work had shown that a high dose of pargyline reduced blood glucose level in obese and non-obese rats (Mattila and Torsti, 1966; Carpene et al., 2007) . Similarly, several studies have reported that competitive inhibition of MAO by high doses of benzylamine or tyramine might also alleviate glucose tolerance in animal models of Type 1 (Marti et al., 2001) or Type 2 diabetes (Visentin et al., 2003) . These reports suggest that although MAO inhibition might have beneficial effects on glucose homeostasis in metabolic derangements, therapeutic and safe doses of selective MAO-B inhibitors might not alleviate glucose tolerance or insulin resistance in obesity. In our present study, neither selegiline treatment nor HFS diet-induced moderate obesity had significant effects on motor activity or recognition memory. Although previous articles showed that extreme obesity induced cognitive dysfunction (Wang et al., 2016; Zanini et al., 2017) , these changes could not be observed in our model of moderate obesity.
The results of mechano-nociceptive tests indicated that HFS diet did not induce peripheral prediabetic neuropathy and that selegiline did not have any effect on the pain threshold either in rats on the HFS diet or on the control diet. However, the metabolic syndrome, including prediabetes can induce peripheral prediabetic neuropathy before progression to clinical Type 2 diabetes (Novella et al., 2001; Sumner et al., 2003) . Relatively little is known about the effect of MAO-B inhibitors on pain or analgesia. Hozumi et al. found that obesity and moderate overweight can negatively affect neuropathic pain intensity and nerve damage, although they could not find the pathophysiological mechanisms behind these findings (Hozumi et al., 2016) . In our study, we showed that moderate obesity does not influence sensory functions.
In summary, this is the first demonstration that selegiline reduces subcutaneous and visceral fat depots in diet-induced obesity. Furthermore, selegiline may influence glucose and lipid metabolism of white adipose tissue and may also alleviate inflammation in white adipose tissue. These results suggest that specific inhibition of MAO-B by selegiline may mitigate some harmful effects of obesity and reduce the risk of cardiovascular diseases. In this way; selegiline may serve as an adjuvant to anti-obesity therapy.
Limitations of the study
Despite all our efforts, our study has certain limitations. Although we did not measure the activity of MAO-B in different organs in this project, we have applied a dose of selegiline widely used in rats that was reported to effectively inhibit MAO-B in several organs (Knoll, 1978; Heinonen et al., 1994; Haberle et al., 2002) . Neither diet nor selegiline had any influence on adipocyte area and weight of interscapular brown adipose tissue. These data indicate that the amount of brown adipose tissue or fat browning might not have been affected by selegiline treatment in rats under HFS diet. Although we found interesting information about the most important fatty tissue, visceral adipose tissue, the results were not compared with those from subcutaneous adipose tissue. In this study, we had no means to measure fuel efficiency and whether it is influenced by HFS diet or selegiline. Furthermore, we have no information about the status of absorption or elimination of nutrients in HFS diet, which might also modulate energy metabolism despite the observed equal caloric intake. Although hormonal balance and energy metabolism significantly differ between males and females, which may modulate the effect of selegiline on obesity, in this study, we did not examine the energy metabolism in female rats. Therefore, oral administration of selegiline should be performed in male and female animals to obtain a clear proof of concept of its usefulness in the treatment of obesity.
Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article.
https://doi.org/10.1111/bph.14437 (   Table S1 Sequences of primers. Table S2 Adipocyte area CON-control (n = 10); CON+S-control+selegiline (n = 10); HFS-high-fat, high-sucrose (n = 9); HFS + S-high-fat, high-sucrose+selegiline (n = 10). Table S3 Number of macrophages in adipose tissue samples CON-control (n = 10); CON+S-control+selegiline (n = 10); HFS-high-fat, high-sucrose (n = 9); HFS + S-high-fat, high-sucrose+selegiline (n = 10).
